Analysis of Churg Strauss Syndrome market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Churg Strauss Syndrome is an extremely rare auto-immune condition which restricts blood flow to vital organs, especially skin and lungs. Churg Strauss syndrome is an over-reactive immune response which is triggered by a combination of environmental factors and genes.
At times, it can also permanently damage the organs and lead to life-threatening complications. Churg Strauss Syndrome is also known as polyangiiti or eosinophilic granulomatosis with polyangiiti. Churg Strauss syndrome has symptomatic three stages: Allergic, Eosinophilic and Vasculitic.
The most common symptom includes asthma. Churg Strauss Syndrome is generally characterized by clusters of white blood cells, in blood and vessels causing blood vessel inflammation. This syndrome is particularly prevalent in aged individuals and individuals with history of nasal allergies, sinus or asthma.
Although there are no specific tests available for diagnosis for Churg Strauss Syndrome, certain blood tests, biopsy procedures, imaging techniques. The treatment includes immunosuppressant drugs, biologics, immunoglobulins and other steroids to control symptoms. Changing environmental conditions leading to several allergies and other immune related disorders and ailments have highly influenced the Churg Strauss syndrome market.
According to U.S. Food and Drug Administration approximately 0.11 to 2.66 new cases per 1 million people are diagnosed with Churg Strauss Syndrome. Initially, being a seldom prognostic disorder, Churg Strauss Syndrome was overlooked and went underdiagnosed but due to research and medical development, Churg Strauss Syndrome is suspected by clinical evaluation.
Churg Strauss Syndrome patients are treated with prednisone or methylprednisonone or other corticosteroid medication which are immunosuppressant, a generic medicine. The medication for Churg Strauss Syndrome is determined by the Five Factor Score (FFS) for the respective patient.
Second-line therapy in the Churg Strauss syndrome is anti-IgE antibodies and plasma exchange. The need for effective and specific medicine foe Churg Strauss syndrome is very evident and exponentially increasing. . Extensive research is being undertaken and studied for drugs like , rituximab, interferon alphaand anti-interleukin-5 (IL-5) as promising treatment for individuals with Churg-Strauss syndrome in the United States of America and Europe.
The global market for Churg Strauss syndrome is expected to grow dependent on the cases reported and advance medical and clinical procedures and computational means in drug discovery. Majority of the Churg Strauss syndrome growth is related to the proper diagnosis and awareness push the need for medication.
Treatment options for Churg Strauss syndrome have witnessed consistent evolution through years, enabling higher suppression of symptoms and improvement in the condition. The first drug with the motivation to cure Churg Strauss Syndrome was introduced by the U.S.
Food and Drug Administration in December 2017 named Nucala manufactured by GlaxoSmithKlineMajor. Manufacturers are more focused on developing drugs for hyper-eosinophilia conditions for better efficiency and long-lasting capabilities.
Immunosuppressant drugs highly contribute to the Churg Strauss syndrome market. High global market revenue is expected upon availability and distribution of Churg Strauss Syndrome drugs, as the market for Churg Strauss Syndrome drugs is wide open.
Geographically, the Churg Strass syndrome market is segmented into viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, China and the Middle East and Africa (MEA). North America is expected to be dominant market in the Churg Strauss syndrome market owing to the presence of key market players and the advance research facilities.
Europe is expected to have second large share in the global Churg Strauss syndrome market throughout the forecast period owing to the expansive research and the epidemiology study conducted in the United Kingdom for ten years data indicated that the incidence of Churg Strauss Syndrome is increasing.
According to a nationwide survey carried out in Japan, the prevalence of Churg Strauss Syndrome is mostly similar to those of Western countries. The market in Asia Pacific excluding Japan is expected to witness moderate growth because of the reason being the disease having seldom incidence and the priority to focus on the cure to more prevalent diseases.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
Manufacturers for the Churg Strauss syndrome market include: Heron Therapeutics, Inc., Silvergate Grifols, GlaxoSmithKlineMajor, Roxane Laboratories, Inc., Hikma Pharmaceutical Corp., Rx Pharma, Novartis, Schein Pharmaceutical Inc.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Tentatively, the global Churg Strauss syndrome market can be segmented on the basis of the route of administration, indication, by distribution channel.
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesPre Book
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
Dominant countries are USA, Asia-Pacific, Japan, China and the Middle East and Africa
Hospital Pharmacies Drives Most Demand For Churg Strass syndrome Market
Need An Exclusive Report For Your Unique Requirement?